摘要
目的 :评价硝苯地平和倍他乐克单用与联用治疗原发性高血压的药物经济学效果。方法 :原发性高血压患者 90例随机分 3组各 3 0例 ,A组给予给予倍他乐克片 2 5mg ,B组硝苯地平片 10mg ,C组硝苯地平和倍他乐克合用 ,剂量与A、B组相同 ,3组用法均为bid ,po ,疗程均为 4周 ,运用药物经济学成本 效果分析方法评价。结果 :A、B、C组总成本分别为 3 5 .5 ,5 6.9,78.4元 ,其效果分别为 82 .1% ,82 .8% ,90 .0 % ,成本 效果比分别为 0 .43 ,0 .69,0 .87。结论
Objective:To evaluate the pharmacoeconomic effect of nifedipin and metoprolol used alone and in combination in the treatment of hypertension. Methods: 90 patients with essential hypertension were randomly divided into 3 equal groups: A, B and C. Patients of group A were given each 25 mg of metoprolol PO, b.i.d.; patients of group B, 10 mg of nifedipine PO, b.i.d.; those of group C, both nifedipine and metoprolol in the same dose as in group A and B, PO, b.i.d. The course of treatment in all 3 groups lasted 4 weeks. Results:The total costs of group A, B and C schemes were 35.5,56.9,and 78.4 yuan, respectively, while the effective rates were 82.1%, 82.8% and 90.0%, respectively. The cost effect ratios were found to be 0.43, 0.69 and 0.87, respertively. Conclusion:Nifedipine in combination with metoprolol was shown to be the best scheme for the treatment of essential hypertension.
出处
《医药导报》
CAS
2003年第8期533-534,共2页
Herald of Medicine
